Improving Pneumococcal Vaccination Rates in an Inpatient Pediatric Diabetic Population

REFERENCES

1. 1.↵
   1. Berical AC,
   2. Harris D,
   3. Dela Cruz CS,
   4. Possick JD

   . Pneumococcal vaccination strategies. An update and perspective. Ann Am Thorac Soc. 2016;13(6):933-944. doi: 10.1513/AnnalsATS.201511-778FR

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Atkinson W,
   2. Wolfe C,
   3. Hamborsky J

   , eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Public Health Foundation; 2011.
3. 3.↵
   1. Muhammad RD,
   2. Oza-Frank R,
   3. Zell E,
   4. et al.

   Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis. 2013;56(5):e59-e67. doi: 10.1093/cid/cis971

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Nuorti JP,
   2. Whitney CG

   ; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1-18.

   OpenUrlPubMed
5. 5.↵
   Louisiana Immunization Network (LINKS). Louisiana Department of Health. Accessed July 27, 2022. lalinks.org/linksweb/
6. 6.↵
   Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102-1106.

   OpenUrlPubMed
7. 7.↵
   1. Torres A,
   2. Blasi F,
   3. Dartois N,
   4. Akova M.

   Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-989. doi: 10.1136/thoraxjnl-2015-206780

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Kuo CS,
   2. Lu CW,
   3. Chang YK,
   4. et al.

   Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine (Baltimore). 2016;95(26):e4064. doi: 10.1097/MD.0000000000004064

   OpenUrlCrossRef
9. 9.↵
   1. Trovato A,
   2. Gunning K,
   3. Pippitt K

   . Vaccination rates in patients with medical indications for the pneumococcal polysaccharide vaccine in a family medicine clinic. J Pharm Pract. 2019;32(2):154-157. doi: 10.1177/0897190017745411

   OpenUrlCrossRef
10. 10.↵
    1. Page A,
    2. Harrison A,
    3. Nadpara P,
    4. Goode JR

    . Pharmacist impact on pneumococcal polysaccharide vaccination rates in patients with diabetes in a national grocery chain pharmacy. J Am Pharm Assoc (2003). 2020;60(3S):S51-S55.e1. doi: 10.1016/j.japh.2020.02.007